Form 4: Kiran Mazumdar-Shaw Reports Changes in Beneficial Ownership of Bicara Therapeutics Inc. Following IPO

Kiran Mazumdar-Shaw, a director and 10% owner of Bicara Therapeutics Inc., reports changes in beneficial ownership due to the conversion of preferred stock to common stock following the company's initial public offering.

Summary

• Kiran Mazumdar-Shaw, a director and 10% owner of Bicara Therapeutics Inc. (BCAX), filed a Form 4 detailing changes in beneficial ownership.
• The changes are primarily due to the automatic conversion of Series Seed Redeemable Convertible Preferred Stock into common stock upon the closing of Bicara Therapeutics' initial public offering (IPO).
• The conversion ratio was 9.2435-to-one.
• Mazumdar-Shaw holds shares indirectly through several entities: Biocon Limited, Biocon Pharma Inc., Glentech International, and Carica Investments.
• She disclaims beneficial ownership of these shares except to the extent of her pecuniary interest.
• Mazumdar-Shaw also acquired 23,746 stock options with an exercise price of $18, vesting on the earlier of August 16, 2025, or the next Annual Meeting of Stockholders, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction following an IPO, indicating a neutral to slightly positive sentiment as it simplifies the company's capital structure. The granting of stock options is also a positive sign of incentivizing key personnel.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• The acquisition of stock options incentivizes Mazumdar-Shaw to continue serving as a director.

Industry Context

Form 4 filings are standard practice following significant events like IPOs, providing transparency into the ownership structure of publicly traded companies. This filing indicates the conversion of preferred shares held by insiders into common shares, a typical step in the post-IPO process.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a slight dilutive effect on existing common shareholders.
• The granting of stock options aligns the interests of management with those of shareholders.

Key Dates